Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity

Inclusion criteria

• 1. Female patients aged 18 to 75 years, diagnosed with gynecological malignancies through histology or cytology.
• 2. Patients who are preparing for monotherapy or combination therapy with ICIs.
• 3. Voluntary signing of informed consent form.
• 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• 5. Expected survival of at least 6 months.

Exclusion criteria

• 1. Previously received ICIs treatment.
• 2. With allergies or contraindications to ICIs.
• 3. Confirmed to be brain metastasis.
• 4. Patients who have major surgery within 4 weeks prior to or following the screening period.
• 5. Patients who have received systemic corticosteroids (at a dose equivalent to >10 mg prednisone per day) or other immunosuppressive medications within 14 days prior to enrollment or during the study period; however, the following situations are allowed for inclusion:

• the use of topical or inhaled corticosteroids is permitted;
• short-term (≤7 days) use of corticosteroids for prevention or treatment of non-autoimmune diseases is allowed.
• 6. Left ventricular ejection fraction (LVEF) ≤50%, or New York Heart Association functional classification (NYHA) ≥III.
• 7. Coronary heart disease, cardiomyopathy, congenital heart disease, valvular heart disease and pericardial diseases with confirmed diagnosis.
• 8. Lack of autonomous capacity, or a documented history of mental disease.
• 9. MRI contraindications: Pacemakers, neurostimulators, artificial metal heart valves, arterial aneurysm clips, intraocular metallic foreign bodies, inner ear implants, metal prostheses, metal limbs, metal joints, and any other metallic implants or foreign objects; severe hyperthermia patients; claustrophobia; severe respiratory conditions that prevent breath-holding.